Home

Jiangsu Hengrui Medicine products

Jiangsu Hengrui Medicine Co., Ltd.offers products and services includingActive Pharmaceutical Ingredients,Finished Dosage. Explore the list of products and services, and send inquiry Jiangsu Hengrui Medicine is a global pharmaceutical company engaged in the research, development, manufacturing and sales of healthcare products, including antineoplastic drugs, angiomyocardiac drugs, surgical drugs, contrast agents and antibiotics

Products and services of Jiangsu Hengrui Medicine Co

Certificate of GMP Compliance | NL/H 11/0085 | Jiangsu

Jiangsu Hengrui Medicine Healthcar

Jiangsu Hengrui Medicine develops, manufactures, and markets a variety of medicines and medicine packing materials. Its products include anti-tumor medicines, pain-killers, anti-infection medicines, aluminum foil, and other related products History. Founded in 1970, Jiangsu Hengrui Medicine was originally state-owned and called Lianyungang Pharmaceutical Factory (Chinese: 连云港制药厂).Headquartered in Lianyungang, Jiangsu, it was established in its current form in 1977.The company was listed on the Shanghai Stock Exchange in 2000 and now has locations in China, the United States, Germany, Switzerland, Japan, and Australia Jiangsu Hengrui Medicine Co. Ltd. is a pharmaceutical company which engaged in the research, development, manufacturing and sales of healthcare products, including antineoplastic drugs, angiomyocardiac drugs, drugs for surgery, contrast agents and antibiotics. Private/Public: public Jiangsu Hengrui Medicine will be responsible for all development, regulatory and commercialization activities and related expenses in the territory. About Jiangsu Hengrui Medicine Co., Ltd. Jiangsu Hengrui Medicine Co., Ltd. established in 1970, is a leading biopharmaceutical company based in China with annual net sales of about $2.5 billion in.

Category:Active Pharmaceutical Ingredients > Anesthetics Product Name:Desflurane CAS No.:57041-67-5 Standard:ChP Price(USD):0.00 Company:Jiangsu Hengrui Medicine Co. BRIEF-Jiangsu Hengrui's Board Elects Chairman. Aug 4 (R) - Jiangsu Hengrui Medicine 600276.SS: SAYS BOARD ELECTS SUN PIAOYANG AS CHAIRMAN. Source text in Chinese: https://bit.ly/3Cb9vnk. Further company coverage: 600276.SS. (Reporting by Hong Kong newsroom) ( ( twinnie.siu@tr.com; 852-3462 7715;)) Related Jiangsu Hengrui Medicine Company Limited, also known as Jiangsu Hengrui Medicine, is a Chinese pharmaceutical company which engaged in the research, development, manufacturing and sales of healthcare products, including antineoplastic drugs, angiomyocardiac drugs, drugs for surgery, contrast agents and antibiotics

Quality product on sale from Jiangsu Hengrui Medicine Co., Ltd., China supplier and buyer on Drugdu.co Jiangsu Hengrui Medicine develops, manufactures, and markets a variety of medicines and medical packing materials. The Company's products include anti-tumor medicines, painkillers, anti-infection medicines, aluminum foil, and other related products. Taking the slogan that Science & Technology for a Better Life, Hengrui Medicine is JIANSU HENGRUI MEDICINE CO., LTD. is a China-based company, principally engaged in the manufacture and distribution of pharmaceutical tablets, injections and raw materials. The Company's main. Jiangsu Hengrui Medicine Company Limited is a Chinese pharmaceutical company engaged in the R&D, manufacturing and sales of healthcare products, including antineoplastic drugs, angiomyocardiac drugs, drugs for surgery, contrast agents and antibiotic JIANGSU HENGRUI MEDICINE CO., LTD. : Trading strategies, financial analysis, commentaries and investment guidance for JIANGSU HENGRUI MEDICINE CO., LTD. Stock.

Jiangsu Hengrui Medicine Co is developing famitinib against a wide variety of advanced-stage solid cancers. The drug is currently in phase 3 of clinical development for the treatment of. Jiangsu Hengrui Medicine Co., Ltd. (600276.SS) Shanghai - Shanghai Delayed Price. Currency in CNY. As of 1:14PM CST. Market open. *Close price adjusted for splits. **Adjusted close price adjusted. Ketamine, supplied by Jiangsu Hengrui Medicine, used in various techniques. Bioz Stars score: 92/100, based on 34 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more. Price from $9.99 to $1999.99 About Jiangsu Hengrui Medicine Co., Ltd. Jiangsu Hengrui Medicine Co., Ltd. is a global biopharmaceutical company, headquartered in China, with 24,700 employees devoted to empowering healthier.

Jiangsu Hengrui Medicine - Forbe

Baxter, Halocarbon Products, AbbVie, Piramal Enterprises, Fresenius Kabi, Jiangsu Hengrui Medicine In 2020, the global Inhalational Anesthesia Drugs market size was million US$ and it is expected to reach a million US$ by the end of 2027, with a CAGR between 2021 and 2027. Get a Sample PDF Report Jiangsu Hengrui Medicine Co., Ltd. engages in the research, development, manufacture, and sale of drugs. It specializes in antineoplastic agents, surgical anesthesia drugs, features infusion, contrast agents, and cardiovascular drugs. The company's products include tablets, oral solution, and suspension of antineoplastic drugs and narcoti This EXCLUSIVE OPTION AND LICENSE AGREEMENT (this Agreement) is entered into as of January 4 th, 2018 (the Effective Date), by and between Arcutis, Inc., a United States corporation incorporated in the State of Delaware with offices at 70 Willow Road, Suite 200, Menlo Park, CA 94025 (Arcutis) and Jiangsu Hengrui Medicine Co.

View the latest Jiangsu Hengrui Medicine Co. Ltd. A (600276) stock price, news, historical charts, analyst ratings and financial information from WSJ Jiangsu Hengrui Medicine Company Limited, also known as Jiangsu Hengrui Medicine, is a Chinese pharmaceutical company which engaged in the research, development, manufacturing and sales of healthcare products, including antineoplastic drugs, angiomyocardiac drugs, drugs for surgery, contrast agents and antibiotics. [1 In the world wide, giant manufactures mainly distribute in US, Europe and China such as Sanofi-Aventis, Yakult honsha, Dr Reddy's laboratories, Teva and Jiangsu Hengrui Medicine By Company Pfizer Athenex AuroMedics Zydus American Regent Hikma Mylan Par Sterile Products Sagent Jiangsu Hengrui Medicine 6.10 Jiangsu Hengrui Medicine 6.10.1 Jiangsu Hengrui Medicine.

JIANGSU HENGRUI MEDICINE CO

Jiangsu Hengrui Medicine Co., Ltd. - NDC products NDC labeler, manufacturer of drugs and pharmaceuticals. Products with assigned NDCs are displayed. Select the NDC to see product information. Select the Trade Name to see similar products. NDC Trade Name Labeler Name; 57884-3061 The headquarters of Jiangsu Hengrui Pharmaceutical Co., Ltd in Lianyungang Economic and Technological Development Zone, east China's Jiangsu Province, Feb 16, 2021. Hengrui Pharmaceutical (600276.SH) has a market value of 553.219 billion yuan Jiangsu Hengrui Pharmaceuticals Co., Ltd. is located in Lianyungang, Jiangsu, China and is part of the Pharmaceutical and Medicine Manufacturing Industry. Jiangsu Hengrui Pharmaceuticals Co., Ltd. has 28903 total employees across all of its locations and generates $4.21 billion in sales (USD) Hengrui Medicine is a leading pharmaceutical company based in China with a focus on research, development, manufacturing, and commercialization of innovative and high-quality healthcare products

Jiangsu Hengrui Medicine Company Profile - Office

Jiangsu Hengrui Pharmaceuticals Co Ltd is a China-based company principally engaged in the manufacture and distribution of pharmaceutical tablets, injections and raw materials. The Company's main products portfolio consists of antineoplastic drugs, angiomyocardiac drugs, drugs for surgery, contrast agents, antibiotics, specialty infusions and. Jiangsu Hengrui Medicine Co. Ltd. received approval from the National Medical Products Administration to market cancer drug camrelizumab in China. Camrelizumab belongs to a class of cancer drugs known as PD-1 checkpoint inhibitors. PD-1 drugs work by blocking interactions between tumor cells and T cells, a key component of the immune system.

PPT - Jiangsu Hengrui Medicine Co

Jiangsu Hengrui Medicine - Wikipedi

Management tracks: Sun departs as Hengrui chair; plus Blackstone, Ipsen, bluebird, BioNTech, Catalent, Foundation, Twist, Lantheus, Abcam and more. Jiangsu Hengrui Medicine Co Ltd. (Shanghai:600276) said Piaoyang Sun will step down as chairman. Sun, who has led the company for 30 years, will continue to serve on the board's strategy committee. About Jiangsu Hengrui Medicine Co., Ltd. Jiangsu Hengrui Medicine Co., Ltd. is a global biopharmaceutical company, headquartered in China, with 24,700 employees devoted to empowering healthier lives through research Jiangsu Hengrui Medicine was founded in 1970 in China. The company focuses on the development of cancer treatments. Further, it produces MedTech products, contrast agents, surgical medicines as well as prescription drugs for diabetes, pain management, and autoimmune diseases Jiangsu Hengrui Medicine Co., Ltd., established in 1970, is the largest research and manufacturing base of antineoplastics and surgical medicine in China. Hengrui Group consists of four parts, the headquarter is located in Lianyungang, Jiangsu Province, another three R&D centers andproduction basesare respectively located in Shanghai, Chengdu. Jiangsu Hengrui Medicine Co., Ltd. Headquarters Address: No.7, Kunlunshan Road, Economic & Technological Development Zone, Lianyungang, Jiangsu, Chin

Jiangsu Hengrui Pharmaceutical Co., Ltd. is a medical and health enterprise engaged in medical innovation and high-quality drug R&D, production, and promotion. It was listed on the Shanghai Stock Exchange in 2000. Hengrui is a well-known supply of anti-tumor drugs, surgical drugs, and contrast agents in China Trials 0 40 80 120 160 200 240 280 320 360 400; AiTan (rivoceranib) / HLB Bio Group; AiRuiKa (camrelizumab) / Incyte; Irene (pyrotinib) / Jiangsu Hengrui Medicine; fluzoparib (SHR 3162) / Jiangsu Hengrui Medicine; famitinib (SHR 1020) / Jiangsu Hengrui Medicine; dalpiciclib (SHR6390) / Jiangsu Hengrui Medicine; SHR-1701 / Jiangsu Hengrui Medicine; SHR0302 / Reistone Biopharma, Jiangsu Hengrui. The mouse pups at P7 were exposed to 2.6% sevoflurane (Jiangsu Hengrui Medicine Co., Ltd., Lianyungang, China) for 6 h [~1.0 minimal alveolar concentration (MAC) in P7 mice] in 50% oxygen in a temperature-controlled chamber, following a previously described protocol (n=12) ( ).. The control mice were exposed to normal air for 6 h under the.

Jiangsu Hengrui Medicine Co

  1. BRIEF-Jiangsu Hengrui's Board Elects Chairman. Aug 4 (R) - Jiangsu Hengrui Medicine 600276.SS: SAYS BOARD ELECTS SUN PIAOYANG AS CHAIRMAN. Source text in Chinese: https://bit.ly/3Cb9vnk. Further company coverage: 600276.SS. (Reporting by Hong Kong newsroom) ( ( twinnie.siu@tr.com; 852-3462 7715;)) Related
  2. Products on ANDA 206812 Drug Name Active Ingredients Strength Dosage Form/Route Marketing Status TE Code RLD RS; FONDAPARINUX SODIUM: FONDAPARINUX SODIUM: 2.5MG/0.5ML: INJECTABLE;SUBCUTANEOUS: JIANGSU HENGRUI MED.
  3. Jiangsu Hengrui Pharmaceuticals Co Ltd. 600276. Morningstar Rating. Rating as of Jul 14, 2021. Quote Stock Analysis News Price vs Fair Value Sustainability Trailing Returns Financials Valuation.
  4. About Jiangsu Hengrui Medicine Co., Ltd. Jiangsu Hengrui Medicine Co., Ltd., established in 1970, is a leading biopharmaceutical company based in China with annual net sales of over $1.6 billion in 2016

Jiangsu Hengrui Medicine : Welcome, Profile Billing Logout . 57 Products : 48 Diseases : 820 Trials : 4173 News « 1 2. Jiangsu Hengrui Pharmaceuticals Co., Ltd. engages in the research, development, manufacture, and sale of drugs. It specializes in antineoplastic agents, surgical anesthesia drugs, features. Jiangsu Hengrui Medicine Co Ltd (Jiangsu Hengrui) is a biopharmaceutical company that focuses on the research, development, manufacture and distribution of novel pharmaceutical products. Its product portfolio includes antineoplastic products, anti-tumor drugs, surgical drugs and contrast agents Currently overseas products range is limited. But in future it will have wide range as company is working on new molecules and different formulations. Glassdoor has 4 Jiangsu Hengrui Medicine reviews submitted anonymously by Jiangsu Hengrui Medicine employees. Read employee reviews and ratings on Glassdoor to decide if Jiangsu Hengrui. Trade data on Jiangsu Hengrui Medicine Co., Ltd.. See Jiangsu Hengrui Medicine Co., Ltd. 's products and customers Thousands of companies like you use Panjiva to research suppliers and competitors

Jiangsu HengRui Medicine Co., Ltd. ClinicalTrials.gov Identifier: NCT04521192 Other Study ID Numbers: FZPL-I-BE-001 : First Posted: August 20, 2020 Key Record Dates: Last Update Posted: August 20, 2020 Last Verified: August 202 JIANSU HENGRUI MEDICINE CO., LTD. is a China-based company, principally engaged in the manufacture and distribution of pharmaceutical tablets, injections and raw materials. The Company's main products portfolio consists of an. tineoplastic drugs, angiomyocardiac drugs, drugs for surgery, contrast agents, antibiotics, specialty infusions and others About Jiangsu Hengrui Medicine Co., Ltd. Jiangsu Hengrui Medicine Co., Ltd. established in 1970, is a leading biopharmaceutical company based in China with annual net sales of about $2.5 billion.

Company profile for Jiangsu Hengrui Medicine Co. Ltd. A including key executives, insider trading, ownership, revenue and average growth rates. View detailed 600276.CN description & address July 9 (R) - Jiangsu Hengrui Medicine Co Ltd 600276.SS: SAYS CHAIRMAN ZHOU YUNSHU RESIGNS DUE TO PERSONAL REASONS. Source text in Chinese: https://bit.ly/3qXKTJr. Further company coverage: 600276.SS (Reporting by Hong Kong newsroom) ((twinnie.siu@tr.com; 852-3462 7715;) Inhalational Anesthesia Drugs Market by Manufacturers, Regions, Type and Application, Forecast To 2026 - Baxter, AbbVie, Piramal Enterprises, Halocarbon Products, Jiangsu Hengrui Medicine, Fresenius Kabi, and mor DDO-3055: Jiangsu HengRui Medicine Co., Ltd. Jiangsu HengRui Medicine is conducting a randomized, double-blind, dose-escalating, placebo controlled, phase I study to evaluate the safety and. About Jiangsu Hengrui Medicine Co., Ltd. Jiangsu Hengrui Medicine Co., Ltd., established in 1970, is a leading biopharmaceutical company based in China with annual net sales of over $2.2 billion.

Jiangsu Hengrui Medicine Co., Ltd. develops, manufactures, and markets a variety of medicines and medicine packing materials. The Company's products include anti-tumor medicines, pain-killers. Jiangsu Hengrui Medicine Co., Ltd. is a global biopharmaceutical company, headquartered in China, with 24,700 employees devoted to empowering healthier lives through research. With over $3.3 billion in revenue in 2019, Hengrui has 6 new molecular entities approved in China as well as 30 plus programs in clinical development in China, US, EU and. Over the past year, Hengrui, China's largest pharma company, has received half-a-dozen approvals from the FDA, giving global sales at the generic- and innovative-drugs manufacturer a boost—and. Fuzuloparib (AiRuiYi ®, 艾瑞颐; formerly fluzoparib) is a PARP inhibitor being developed by Jiangsu Hengrui Pharmaceuticals Co., Ltd. (formerly Jiangsu Hengrui Medicine Co., Ltd.) for the treatment of recurrent ovarian cancer (including fallopian tube cancer or primary peritoneal cancer) and other solid cancers.Fuzuloparib is the first original PARP inhibitor to be developed in China and.

Novaliq and Jiangsu Hengrui Medicine announce a strategic

  1. Jiangsu Hengrui Medicine Co., Ltd. engages in the research, development, manufacture, and sale of drugs. It specializes in antineoplastic agents, surgical anesthesia drugs, features infusion, contrast agents, and cardiovascular drugs
  2. obutyric Acid Receptor Subunit Gamma 2 Market report provides brief information of the specific growth opportunities with trends of Top Manufacturers- Jiangsu Hengrui..
  3. Journal: Annals of Translational Medicine doi: 10.21037/atm-20-6063 Figure Legend Snippet: Kaplan-Meier curve showing progression‐free survival for the entire cohort of patients treated with programmed cell death protein‐1 (PD‐1)-targeted immunotherapy
  4. Rheumatoid Arthritis (RA) - Pipeline Insight, 2021 report by the publisher outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Rheumatoid Arthritis (RA) pipeline landscape is provided which includes the disease overview and Rheumatoid Arthritis (RA) treatment guidelines

Jiangsu Hengrui Pharmaceuticals is a global pharmaceutical company engaged in the research, development, manufacturing and sales of healthcare products, including antineoplastic drugs, angiomyocardiac drugs, surgical drugs, contrast agents and antibiotics. The company was established in 1997 and is headquartered in Lianyungang, Jiangsu. It was. Jiangsu Hengrui Medicine Co., Ltd., established in 1970, having over 17,000 employees globally, is the largest manufacturer of antineoplastic drgus, surgical drugs and contrast media in China. Its operating income was over USD 2.4 billion in 2017. The company stock was officially listed on the Shanghai Stock Exchange in 2000 * This phone number available for 3 min is not the recipient's number but a number from a service which will put you through to that person. This service is produced by Kompass Hengrui has been the hotspot of the medical world recently. According to an announcement of Hengrui Medicine previously, Sun Piaoyang will step down as the chairman of Hengrui, however, he will continue to serve as a director and the chairman of the strategic committee under the Board of Directors of the company; Zhou Yunshu who has served as the general manager for 17 years will serve as the.

Jiangsu Hengrui Medicine Co. Ltd. A. Jiangsu Hengrui Pharmaceuticals Co., Ltd. engages in the research, development, manufacture, and sale of drugs The Basel life sciences ecosystem is set to grow by another major global player. The international company Hengrui Medicine is establishing a Swiss subsidiary, Hengrui Europe Therapeutics AG. Founded in 1970, the Chinese company reportedly has a market capitalization of about $70 billion and therefore ranks as one of the top 30 life sciences companies in the world Jiangsu Hengrui Medicine Co., Ltd. at . Find their customers, contact information, and details on 96 shipments Jiangsu Hengrui Medicine Co Ltd (Jiangsu Hengrui) is a biopharmaceutical company that focuses on the research, development, manufacture and distribution of novel pharmaceutical products. Its product portfolio includes anti-tumor drugs, surgical drugs and contrast agents

Jiangsu Hengrui Pharmaceuticals Co Ltd 600276. Jiangsu Hengrui Pharmaceuticals Co Ltd. 600276. Morningstar Rating. Rating as of Jun 29, 2021. Quote Stock Analysis News Price vs Fair Value Trailing. Glassdoor gives you an inside look at what it's like to work at Jiangsu Hengrui Medicine, including salaries, reviews, office photos, and more. This is the Jiangsu Hengrui Medicine company profile. All content is posted anonymously by employees working at Jiangsu Hengrui Medicine

Desflurane Jiangsu Hengrui Medicine Co

Jiangsu Hengrui Medicine market of the new products and so on, the performance growth slowed down was also a result of the Company's over-leaning towards innovative drugs, which resulted in overlooking the varieties of the generic drugs for reserve use and thus caused 57 Products : 48 Diseases : 820 Trials : 4173 News : Active Status Sponsor type Region Phase Filter; 993 Active 160 Inactive 1153 All. Not yet recruiting Recruiting Enrolling by invitation Active, not Jiangsu HengRui Medicine Co., Ltd. Breast Cancer. 09/28. 09/33

Jiangsu Hengrui Medicine Co., Ltd., established in 1970, is a leading biopharmaceutical company based in China with annual net sales of over $2.2 billion in 2017. Hengrui is devoted to empowering healthier lives through research, with a team of over 20,000 employees in China, the United States, Australia, Japan and Germany Jiangsu HengRui Medicine Co., Ltd. ClinicalTrials.gov Identifier: NCT04455581 Other Study ID Numbers: SHR-1209-201 : First Posted: July 2, 2020 Key Record Dates: Last Update Posted: July 2, 2020 Last Verified: June 2020 Individual Participant Data (IPD) Sharing Statement: Plan to Share IPD: N

Trade data on Jiangsu Hengrui Medicine Co., Ltd.. See Jiangsu Hengrui Medicine Co., Ltd. 's products and suppliers Thousands of companies like you use Panjiva to research suppliers and competitors About Jiangsu Hengrui Medicine Co., Ltd. Jiangsu Hengrui Medicine Co., Ltd., established in 1970, is a leading biopharmaceutical company based in China with annual net sales of over $2.2 billion in 2017. Hengrui is devoted to empowering healthier lives through research, with a team of over 20,000 employees in China, the United States, Australia. As of 12/3/20. Overall Score. 1.5. Sector. Health Care. Lists ranking Jiangsu Hengrui Medicine. RANK 42. Future 50 - 2020 Explore this year's ranking of the 50 companies wi... READ MORE view in list Jiangsu Hengrui Medicine General Information Description. Jiangsu Hengrui Pharmaceuticals Co Ltd is engaged in the field of cancer treatment drugs, surgical medicines, endocrine therapy drugs, cardiovascular drugs and anti-infection medications

About Hengrui - HENGRUI USA

BRIEF-Jiangsu Hengrui's Board Elects Chairma

Novaliq and Jiangsu Hengrui Medicine, a biopharmaceutical company based in China, announced the closing of an exclusive license agreement to develop, manufacture and commercialize water-free drugs NOV03 and CyclASol for the treatment of dry eye disease in the People's Republic of China (including mainland China, Hong Kong, Macau and Taiwan) HengRui USA is the US hub for our parent company Jiangsu Hengrui Medicine (600276 SHA), a global pharmaceutical company with around $90 Billion market value, $3.6 Billion annual revenue (data by. Founded in 1970, Jiangsu Hengrui Medicine was originally state-owned and called Lianyungang Pharmaceutical Factory ( Chinese: 连云港制药厂 ). Headquartered in Lianyungang, Jiangsu, it was established in its current form in 1977. The company was listed on the Shanghai Stock Exchange in 2000 and now has locations in China, the United States. The companies which have their Gastrointestinal Stromal Tumors drug candidates in the most advanced stage, i.e. phase III include, Jiangsu Hengrui Medicine. Phases Late stage products (Phase III Gastrointestinal Stromal Tumors Pipeline Insight Report 2021 Featuring Emerging Drugs Such as Famitinib: Jiangsu Hengrui Medicine & DS 6157: Daiichi Sankyo Company - ResearchAndMarkets.co

Jiangsu Hengrui Medicine's $87

Food Products Jiangsu Hengrui Medicine: 3.19%: Pharmaceuticals Jiangsu Yanghe Brewery Joint-Stock: 1.13%: Distillers & Vintners Kweichow Moutai: 11.78%: Distillers & Vintners LONGi Green Energy Technology: 2.58%: Luxshare Precision Industry: 1.74%: Telecommunications Equipment Luzhou Laojiao: 2.17%: Midea Group: 1.69%: Durable Household. HengRui USA is the US hub for our parent company Jiangsu Hengrui Medicine (600276 SHA), a global pharmaceutical company with about $90 Billion market value and over 30,000 employees globally. The. Company: HENGRUI EUROPE THERAPEUTICS . Job Title: Pharmacovigilance Physician. Department: Clinical Development department. Location: Basel, Switzerland. About Hengrui: Hengrui is the biggest Chinese pharma company with 25'000 employees, headquartered in Shanghai Famitinib: Jiangsu Hengrui Medicine. Famitinib, an orally active, small molecule, is a tyrosine kinase inhibitor against multiple targets, including vascular endothelial growth factor receptor 2/3, platelet-derived growth factor receptor, and stem cell factor receptor (c-kit)

Sevoflurane Inhalation Anesthetic | Jiangsu HengruiAlfalfa Tonic - Jhactions Homoeo PvtHAO 472 « New Drug ApprovalsLaminar Air Flow Units_Solutions_Wuxi Lenge PurificationChina Regulatory Roundup: AZ Gains PD-L1 Green Light Ahead